A Phase 1 Study of Vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in Combination With Decitabine in Patients With Advanced Solid Tumors, Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia in Blast Crisis.

Trial Profile

A Phase 1 Study of Vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in Combination With Decitabine in Patients With Advanced Solid Tumors, Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia in Blast Crisis.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2014

At a glance

  • Drugs Decitabine (Primary) ; Vorinostat (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Acute promyelocytic leukaemia; Chronic myeloid leukaemia; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 05 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top